GPC1 and in situ carcinoma: Glypican-1+ circulating sEVs (GPC1+crExos) showed 100% sensitivity and specificity for each stage of pancreatic cancer (carcinoma in situ, stage I, and stage II–IV), and has the potential for use as a noninvasive diagnosis and screening tool to detect the early stages of pancreatic cancer and promote curative surgical treatment [141].